Cadila Healthcare’s arm partners with CHEMI of Italy
20th Aug 2021

Zydus Pharmaceuticals Inc, USA (a 100% subsidiary of Cadila Healthcare (Zydus Cadila)) has signed a license and supply agreement with CHEMI SpA (CHEMI) of Italy, a subsidiary of Italfarmaco Group, to launch the generic equivalent of Sanofi Aventis’s branded product Lovenox (Enoxaparin Sodium Injection) in seven dosage strengths in the United States (US).

Under the agreement, CHEMI will manufacture and supply the Enoxaparin Sodium Injection which Zydus will commercialize in the US. CHEMI owns proprietary rights on a pharmaceutical product composed of Enoxaparin Sodium (Preservative Free) single-use pre-filled syringes, which is an AP-rated generic version of the branded product Lovenox. CHEMI, utilizing their proprietary technology, will produce the Enoxaparin Sodium injection within proprietary manufacturing facilities located in Italy. CHEMI within ITF group is also vertically integrated on the Enoxaparin Sodium API manufacturing which ensures quality and an uninterrupted supply of the critical care product.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.